CHICAGO, May 30, 2015 /PRNewswire/ -- GenomeDx
Biosciences today announced that data presented at the 2015
American Society of Clinical Oncology Annual Meeting demonstrate
that the Decipher® Prostate Cancer Classifier is a significant
predictor of metastasis in patients treated with postoperative
salvage radiation therapy. Importantly, patients with a low
Decipher score had excellent outcomes overall, independent of
whether they received early or late salvage radiation, and with or
without concurrent hormone therapy. In contrast, patients with a
high Decipher score had comparatively worse outcomes, although they
had improved metastasis-free survival with early salvage
radiation.
In the study led by investigators at Thomas
Jefferson University and the Durham VA, which evaluated 170
patients who received radiation therapy for a postoperative rising
PSA or biochemical recurrence, only 2.7% of men with a low Decipher
score had metastatic disease within 5 years. Metastasis occurred in
8.4% of men with an intermediate Decipher score and 33.1% of men
who had a high Decipher score. While, in the lower Decipher risk
group there were no significant differences in metastasis
incidence, in the men with higher Decipher risk who received early
salvage radiation had only 7.8% metastasis incidence compared to
28.7% for men who received late salvage radiation (p=0.031). The
study, titled "Validation of a genomic classifier for prediction of
metastasis following postoperative salvage radiation therapy", was
presented today by Adam Dicker,
M.D., Ph.D., Chair of Radiation Oncology at the Sidney Kimmel
Cancer Center at Thomas Jefferson
University.
"Based on these data, we believe that this predictive
technology, using precision medicine, can help us tailor treatment
approaches to fit an individual patient's risk," Dr. Dicker said.
"This may mean avoiding concurrent hormone therapy and delaying
radiation for patients with a low Decipher score, and recommending
earlier radiation and intensification of therapy for patients with
higher Decipher scores."
Also highlighted today, Ashley
Ross, M.D., of The Brady Urologic Institute at Johns Hopkins School of Medicine, presented data
from a study titled "Tissue Based Genomics Augment
Post-Prostatectomy Risk Stratification in a Natural History
Cohort". The study showed that a high Decipher score was
predictive of metastasis after radical prostatectomy in a cohort of
men that received no postoperative therapy prior to metastatic
onset. Decipher was able to predict metastasis free survival at 10
years in this 'natural history' cohort of 260 intermediate and
high-risk men. In the study, the cumulative incidence of metastasis
at 10 years was significantly higher for those men with a high
Decipher score (47%) versus those with low scores (12%). Two
additional abstracts were accepted for publication in the 2015 ASCO
Annual Meeting Proceedings.
The commercially available Decipher Prostate Cancer Classifier
is covered by Medicare and evaluates 22 genomic markers to
accurately & independently predict metastatic onset after
radical prostatectomy for patients with adverse pathology.
The Decipher test was developed by interrogating billions of
genomic data points collected from clinical studies published in
over 20 peer-reviewed articles.
About Decipher®
The Decipher® Prostate Cancer Classifier is a
highly validated and commercially available genomic test for men
with intermediate and high risk prostate cancer. Decipher predicts
cancer aggressiveness by looking for a unique genomic signature
comprised of a validated series of biomarkers associated with
metastatic disease. Adding truly unique information to the
treatment decision-making process, Decipher generates a risk result
that is completely independent and distinct from PSA, Gleason score
and other clinical risk factors. Clinical studies from leading
cancer centers published in over a dozen medical journals
demonstrate that Decipher can accurately predict metastatic
disease, which men may benefit from radiation therapy following
prostate surgery, and can lead to significant cost-savings for
healthcare systems. Decipher was developed in partnership with the
Mayo Clinic.
Decipher is covered by Medicare and multiple private insurance
plans and is available to eligible US patients through their
physicians.
Learn more at: www.DecipherTest.com and follow Decipher on
Twitter at @DecipherTest and on Facebook.
About GenomeDx Biosciences
GenomeDx Biosciences is focused on transforming cancer patient
care by putting usable genomic information in the hands of patients
and their physicians. GenomeDx is developing and commercializing
Decipher®, a highly validated genomic test for
predicting metastatic disease in men with prostate cancer. In
partnership with leading medical centers, the company has assembled
the largest genomic catalogue of prostate cancer tumors in the
world, representing billions of data points and more than 30 years
of prostate cancer clinical experience. Using advanced cloud-based
bioinformatics, GenomeDx mines the genomic data to develop
proprietary tests that address key clinical questions in cancer
patient management. GenomeDx has partnered to share genomic data
with leading clinician-scientists worldwide to collaboratively
enrich the knowledge and understanding of urologic cancers for the
goal of improving global cancer patient care. GenomeDx is based in
San Diego, California and
Vancouver, British Columbia.
Learn more at www.genomedx.com and follow us on Twitter at
@GenomeDx, Facebook, LinkedIn and YouTube.
Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-prostate-cancer-test-is-significant-predictor-of-metastasis-in-patients-with-detectable-psa-following-treatment-with-radiation-after-prostate-surgery-according-to-study-presented-at-asco-2015-annual-meeting-300091180.html
SOURCE GenomeDx Biosciences